Atara Biotherapeutics, headquartered in Thousand Oaks, California, is a biotechnology company specializing in allogeneic T-cell immunotherapy, with products like Ebvallo and ATA3219 in various development stages. The company went public on October 16, 2014, and employs 173 staff.
Jill Henrich sold 1,059 shares of ATRA on 3 March at $7.00 per share, worth a total of $7K. They now own 18,679 ATRA shares, or a 5% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
